Series D extends runway into 2027, advancing first-in-class c-mod DPTX3186 toward proof-of-concept in gastric cancer. Strong support from leading investors and global pharma partners continues to ...
Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026 Data highlight biomarker-linked activity and in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results